MX2013003561A - Composiciones y métodos para tratar la neoplasia. - Google Patents
Composiciones y métodos para tratar la neoplasia.Info
- Publication number
- MX2013003561A MX2013003561A MX2013003561A MX2013003561A MX2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- seq
- chimeric antibody
- chimeric
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38676410P | 2010-09-27 | 2010-09-27 | |
| PCT/EP2011/066791 WO2012041863A1 (en) | 2010-09-27 | 2011-09-27 | Compositions and methods for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013003561A true MX2013003561A (es) | 2013-09-02 |
Family
ID=44675608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003561A MX2013003561A (es) | 2010-09-27 | 2011-09-27 | Composiciones y métodos para tratar la neoplasia. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9115192B2 (https=) |
| EP (1) | EP2621947A1 (https=) |
| JP (1) | JP5946459B2 (https=) |
| KR (1) | KR20140016240A (https=) |
| CN (1) | CN103459420B (https=) |
| AU (1) | AU2011310664B2 (https=) |
| BR (1) | BR112013007327A2 (https=) |
| CA (1) | CA2812644A1 (https=) |
| IL (1) | IL225483A0 (https=) |
| MX (1) | MX2013003561A (https=) |
| SG (1) | SG189095A1 (https=) |
| WO (1) | WO2012041863A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI718086B (zh) | 2013-01-07 | 2021-02-11 | 英屬維爾京群島商遠東超級實驗室有限公司 | 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物 |
| JP6488520B2 (ja) * | 2013-08-20 | 2019-03-27 | 国立研究開発法人科学技術振興機構 | ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法 |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| TWI728975B (zh) * | 2015-05-12 | 2021-06-01 | 英屬維爾京群島商遠東超級實驗室有限公司 | 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7959915B2 (en) | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| US7780963B2 (en) * | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
-
2011
- 2011-09-27 EP EP11760802.6A patent/EP2621947A1/en not_active Withdrawn
- 2011-09-27 MX MX2013003561A patent/MX2013003561A/es not_active Application Discontinuation
- 2011-09-27 AU AU2011310664A patent/AU2011310664B2/en not_active Ceased
- 2011-09-27 CN CN201180056980.1A patent/CN103459420B/zh not_active Expired - Fee Related
- 2011-09-27 SG SG2013022249A patent/SG189095A1/en unknown
- 2011-09-27 KR KR1020137010742A patent/KR20140016240A/ko not_active Withdrawn
- 2011-09-27 JP JP2013529675A patent/JP5946459B2/ja not_active Expired - Fee Related
- 2011-09-27 WO PCT/EP2011/066791 patent/WO2012041863A1/en not_active Ceased
- 2011-09-27 BR BR112013007327A patent/BR112013007327A2/pt not_active IP Right Cessation
- 2011-09-27 CA CA2812644A patent/CA2812644A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/797,194 patent/US9115192B2/en not_active Expired - Fee Related
- 2013-03-24 IL IL225483A patent/IL225483A0/en unknown
-
2015
- 2015-08-21 US US14/832,604 patent/US9328161B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2812644A1 (en) | 2012-04-05 |
| WO2012041863A1 (en) | 2012-04-05 |
| EP2621947A1 (en) | 2013-08-07 |
| US20130280244A1 (en) | 2013-10-24 |
| JP2013541944A (ja) | 2013-11-21 |
| AU2011310664A1 (en) | 2013-05-09 |
| CN103459420B (zh) | 2016-09-28 |
| IL225483A0 (en) | 2013-06-27 |
| US9115192B2 (en) | 2015-08-25 |
| BR112013007327A2 (pt) | 2017-07-04 |
| KR20140016240A (ko) | 2014-02-07 |
| AU2011310664B2 (en) | 2016-02-18 |
| US20160075771A1 (en) | 2016-03-17 |
| SG189095A1 (en) | 2013-05-31 |
| JP5946459B2 (ja) | 2016-07-06 |
| US9328161B2 (en) | 2016-05-03 |
| CN103459420A (zh) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011310664B2 (en) | Compositions and methods for treating neoplasia | |
| CN113544156B (zh) | 抗Claudin18.2抗体及其应用 | |
| US11359021B2 (en) | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| US10208125B2 (en) | Anti-mucin 1 binding agents and uses thereof | |
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| CN102847148A (zh) | 结合细胞内prl-1多肽或prl-3多肽的抗体 | |
| KR20150013935A (ko) | 트랜스포터에 대한 항체 및 이의 용도 | |
| US20220153863A1 (en) | Prame binding molecules and uses thereof | |
| WO2008059616A1 (en) | Antibody recognizing c-domain of midkine | |
| JP2018508206A (ja) | Ｌ型電位開口型チャネルに対する抗体および関連方法 | |
| JP5896568B2 (ja) | 動脈硬化又は動脈硬化性疾患の治療剤、及び動脈硬化又は動脈硬化性疾患の診断薬 | |
| JP6535668B2 (ja) | Ｂ細胞受容体複合体膜結合ＩｇＭを標的とする抗体およびその使用 | |
| US20230062361A1 (en) | Monoclonal antibodies against neonatal nav1.5 | |
| HK40033721A (en) | Anti-mucin 1 binding agents and uses thereof | |
| EP4598961A1 (en) | Glypican 3 antibody and related methods | |
| HK40047979A (en) | Fusion protein and use thereof | |
| HK1226813B (en) | Anti-mucin 1 binding agents and uses thereof | |
| HK1226813A1 (en) | Anti-mucin 1 binding agents and uses thereof | |
| HK1181316B (en) | Notch1 binding agents and methods of use thereof | |
| HK1181316A1 (en) | Notch1 binding agents and methods of use thereof | |
| HK1149483A1 (en) | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |